Technical Analysis for PLX - Protalix BioTherapeutics, Inc.

Grade Last Price % Change Price Change
grade C 0.428 0.71% 0.00
PLX closed up 0.71 percent on Friday, January 18, 2019, on approximately normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical PLX trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Support Bullish 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Crossed Above 50 DMA Bullish 0.71%
Jan 17 Wide Bands Range Expansion 0.71%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 7.54%
Jan 16 Calm After Storm Range Contraction 7.54%
Jan 16 Narrow Range Bar Range Contraction 7.54%
Jan 16 NR7 Range Contraction 7.54%
Jan 16 NR7-2 Range Contraction 7.54%
Jan 16 Inside Day Range Contraction 7.54%

Older signals for PLX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company's product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications; and an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant enzyme produced within carrot cells. Its product pipeline also comprises PRX-106 or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor and an antibody portion, which is being developed as a treatment of certain immune diseases, such as rheumatoid arthritis, Chrohn's disease, placque psoriasis, and other autoimmune disorders; and two additional undisclosed therapeutic proteins that are being evaluated in animal studies. It has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. The company was founded in 1993 and is based in Carmiel, Israel.
Is PLX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 0.83
52 Week Low 0.27
Average Volume 402,237
200-Day Moving Average 0.469
50-Day Moving Average 0.3995
20-Day Moving Average 0.3679
10-Day Moving Average 0.4131
Average True Range 0.0324
ADX 22.8
+DI 26.4097
-DI 16.3216
Chandelier Exit (Long, 3 ATRs ) 0.3728
Chandelier Exit (Short, 3 ATRs ) 0.3672
Upper Bollinger Band 0.4712
Lower Bollinger Band 0.2646
Percent B (%b) 0.79
BandWidth 56.156564
MACD Line 0.0074
MACD Signal Line -0.0018
MACD Histogram 0.0092
Fundamentals Value
Market Cap 57.08 Million
Num Shares 133 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -0.71
Price-to-Sales 6.07
Price-to-Book 0.00
PEG Ratio -0.16
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.49
Resistance 3 (R3) 0.48 0.46 0.48
Resistance 2 (R2) 0.46 0.44 0.46 0.47
Resistance 1 (R1) 0.44 0.43 0.43 0.45 0.47
Pivot Point 0.42 0.42 0.41 0.42 0.42
Support 1 (S1) 0.40 0.40 0.39 0.41 0.39
Support 2 (S2) 0.38 0.40 0.38 0.38
Support 3 (S3) 0.37 0.38 0.38
Support 4 (S4) 0.37